Ces radiol. 2009, 63(4):290-302

A role of 18F-FDG-PET/CT in the treatment decisions of uterine and ovarian tumors, our clinical practice experienceOriginal article

Eva Ferdova1, Jindřich Fínek2, Jiří Ferda1
1 Klinika zobrazovacích metod LF UK a FN, Plzeň
2 Onkologické a radioterapeutické oddělení FN, Plzeň

Aim: To evaluate own experience with the imaging of the gynecological tumors with 18F-FDG-PET/CT including full diagnostic computed tomography and to analyze its optimal clinical indications.

Method: 179 females underwent (mean age 54.7 y., ranging 35-83 years) examination within the sample of following 6000 18F-FDG-PET/CTs, 327 procedures were performed in total. The indications were primary staging, restaging or therapy response evaluation due to the gynecological tumor. Computed tomography was performed as full diagnostic isotropic imaging including reconstruction of lung high resolution images to be able to assess lung parenchyma changes.

Results: During analysis were found 100% of restaging indications in ovarian cancer (215 procedures) including 21 patients with more than two procedures; the primary staging of the cervical carcinoma was performed only in two cases (4.3%), the increased percentage of primary staging was found in the group of endometrial cancer (2/12 e.g. 16%).

Conclusion: According our own experience, the most important indication of the 18F-FDG-PET/CT we found in the evaluation of the ovarian cancer recurrence. The primary staging of the malignancies of the uterus is possible in selected cases, but the most important is also restaging.

Keywords: cervical carcinoma, endometrial carcinoma, leiomyosarcoma of the uterus, 18F-FDG-PET/CT

Accepted: October 15, 2009; Published: December 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ferdova E, Fínek J, Ferda J. A role of 18F-FDG-PET/CT in the treatment decisions of uterine and ovarian tumors, our clinical practice experience. Ces radiol. 2009;63(4):290-302.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Havrilesky LJ, Kulasingam SL, Matchar DB, Myers ER. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol 2005; 97: 193-191. Go to original source... Go to PubMed...
    2. Thrall MM DeLoia JA, Gallion H Avril N. Clinical use of combined positron emission tomogrpahy and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol 2007; 105: 17-22. Go to original source... Go to PubMed...
    3. Grisby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 2001; 19: 3745-3749. Go to original source... Go to PubMed...
    4. Chang TC, Law KS, Hong JH, et al. Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: a phase III study. Cancer 2004; 101: 164-171. Go to original source... Go to PubMed...
    5. Grisby PW, Siegel BA, Dehdashti F, et al. Posttherapy (18F) fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J clin Oncol 2004; 22: 2167-3171. Go to original source... Go to PubMed...
    6. Sakurai H Suzuki Y, Nonaka T, et al. FDG-PET in detection of recurrence of uterine cervical carcinoma following radiation therapy - tumor volume and FDG uptake value. Gynecol Oncol 2006; 100: 601-607. Go to original source... Go to PubMed...
    7. Belhocinte T, De Barsy C, Hustinx R, Willems-Foidart J. Usefullness of (18) F-FDG-PET in the post-therapy suveillance of endometrial carcinoma. Eur J Nucl Med Mol Imaging 2002; 29: 1132-1139. Go to original source... Go to PubMed...
    8. Chao A, Chang TC, Ng KK, et al. 18F-FDG-PET in the management of endometrial cancer. Eur J Nucl Med Mol Imaging 2006; 33: 36-44. Go to original source... Go to PubMed...
    9. Bristow RE, del Carmen MG, Pannu HK, et al. Clinically occult recurent ovarian cancer: patient selection for secondary cytoreduction surgery using combined PET/CT. Gynecol Oncol 2003; 90: 519-528. Go to original source... Go to PubMed...
    10. Chung HH, Kang WJ, Kim JW, et al. Role of the (18)F-FDG PET/CT in the assessm,ent of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging 2007; 34: 480-486. Go to original source... Go to PubMed...
    11. Fenchel S, Grab D Nuessle K, et al. Asymptomatic adnexal masses: correlation ofFDG-PET and histopathological findings. Radiology 2002; 223: 780-788. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content